Lykos laying off 75% of workforce following FDA rejection of psychedelic drug for PTSD [Seeking Alpha]
Mind Medicine (MindMed) Inc. - Common Shares (MNMD)
Company Research
Source: Seeking Alpha
FDA's decision earlier in August to reject its application for an MDMA-based drug to treat PTSD. In addition, Rick Doblin, the co-founder of the Multidisciplinary Association for Psychedelic Studies which incubated Lykos, is stepping down from the company's board. David Hough, a former R&D exec with Johnson & Johnson Innovative Medicine, has been brought on to oversee discussions with the agency and clinical development going forward. Lykos has also formed an independent advisory board to support management through the midomafetamine resubmission process. Publicly traded psychedelic-focused drug developers include Mind Medicine ( NASDAQ: MNMD ), Atai Life Sciences ( NASDAQ: ATAI ), COMPASS Pathways ( NASDAQ: CMPS ), Cybin ( CYBN ), and GH Research ( GHRS Nano-caps include 180 Life Sciences ( ATNF ), Enveric Biosciences ( ENVB ), Seelos Therapeutics ( NASDAQ: SEEL ), SciSparc ( SPRC ), Bright Minds Biosciences ( DRUG ), and Clearmind Medicine ( CMND Recommended For You Re
Show less
Read more
Impact Snapshot
Event Time:
MNMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNMD alerts
High impacting Mind Medicine (MindMed) Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MNMD
News
- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $16.00 to $14.00. They now have a "buy" rating on the stock.MarketBeat
- MindMed Announces New Employee Inducement GrantsBusiness Wire
- MindMed to Participate in September Investor ConferencesBusiness Wire
- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target raised by analysts at HC Wainwright from $35.00 to $55.00. They now have a "buy" rating on the stock.MarketBeat
- Trials for psychedelic drug candidate for PTSD under scrutiny by FDA - report [Seeking Alpha]Seeking Alpha
MNMD
Earnings
- 8/13/24 - Beat
MNMD
Sec Filings
- 9/25/24 - Form 144
- 9/25/24 - Form 4
- 9/25/24 - Form 4
- MNMD's page on the SEC website